The EGFR family of type I growth factor receptor tyrosine kinases includes EGFR (HER1), c-erbB2 (HER2; neu), c-erbB3 (HER3) and c-erbB4 (HER4). EGFR activation signals multiple downstream signalling cascade pathways such as the Ras – ERK, PI3-K – Akt, Jak – STAT and PKC pathways which help in growth and proliferation of cells. Dysregulation of EGFR signalling as a consequence of overexpression, amplification and mutation of the EGFR gene occurs frequently in several types of cancers, including head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, oesophagus, stomach and in squamous cell carcinoma. Tumours become dependent on…
| Inventor | Institute |
|---|---|
| Peter Goodfellow | Cancer Research UK, London Research Institute: Lincoln's Inn Fields |
| Cat. #: | 151090 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer;Cell signaling and signal transduction |
| Application: | FACS ; IHC ; IF ; IP ; WB |
| Target: | Epidermal Growth Factor Receptor (EGFR, Her1) |
| Reactivity: | Human |
| Clone: | EGFR1 |
| Host: | Mouse |
| Class: | Monoclonal |
| Alternate name: | CCNA1; Cyclin A1; Testicular Tissue Protein Li 34; CT146 |
|---|---|
| Product description: | Monoclonal antibody which binds EGFR1 tyrosine kinase, commonly mutated in a range of cancers. |
| Conjugation: | Unconjugated |
| Isotype: | IgG2b kappa |
| Molecular weight: | 175 kDa |
| Immunogen: | Human epidermoid carcinoma line A431 |
| Immunogen Uniprot ID: | P00533 |
| Myeloma used: | P3/NS1/1-Ag4.1 |
| Target background: | The EGFR family of type I growth factor receptor tyrosine kinases includes EGFR (HER1), c-erbB2 (HER2; neu), c-erbB3 (HER3) and c-erbB4 (HER4). EGFR activation signals multiple downstream signalling cascade pathways such as the Ras – ERK, PI3-K – Akt, Jak – STAT and PKC pathways which help in growth and proliferation of cells. Dysregulation of EGFR signalling as a consequence of overexpression, amplification and mutation of the EGFR gene occurs frequently in several types of cancers, including head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, oesophagus, stomach and in squamous cell carcinoma. Tumours become dependent on EGFR signalling to maintain their malignant phenotypes. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | Store at -20° C frozen. Avoid repeated freeze / thaw cycles |
| Shipping conditions: | Dry ice |
| References: |
Finetti et al. 2015. Endocr Relat Cancer. 22(4):665-78. PMID: 26113609. Perillo et al. 2015. Nat Commun. 6:7874. PMID: 26219252. Tang et al. 2015. Oncol Rep. 34(1):350-8. PMID: 25955689. Boersma et al. 2011. J Biol Chem. 286(48):41273-85. PMID: 21979953. Jensen et al. 2006. Proc Natl Acad Sci U S A. 103(32):11958-63. PMID: 16877544. Gullick et al. 1986. Cancer Res. 46(1):285-92. PMID: 2998607. Waterfield et al. 1982. J Cell Biochem. 20(2):149-61. PMID: 6188757. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151022 | Anti-IL12 [1-1A4] |
Key Info
Anti-IL12 [1-1A4]
|
View Tool | |||||||||||||||||||
| 151023 | Anti-IL12 [1-1D5] |
Key Info
Anti-IL12 [1-1D5]
|
View Tool | |||||||||||||||||||
| 151040 | Anti-CD11 & CD18 [24] |
Key Info
Anti-CD11 & CD18 [24]
|
View Tool | |||||||||||||||||||
| 151017 | Anti-MBP [R29.6] |
Key Info
Anti-MBP [R29.6]
|
View Tool | |||||||||||||||||||
| 151020 | Anti-CyclinB1 [V143.1] |
Key Info
Anti-CyclinB1 [V143.1]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.